Hematology

Latest News

After adjustment for imbalances, patients in the liso-cel group had an overall response rate of 52.5%, compared with 19.2% in the standard-of-care group. | Image credit: fotogurmespb- stock.adobe.com
Liso-Cel Improves Outcomes in R/R CLL/SLL Following 2 or More Lines of Therapy

June 26th 2025

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (liso-cel) to a real-world cohort receiving standard therapy.

Multi-hit TP53 mutations are a significant negative prognostic factor for patients with both MPN and AML, the new study found. | Image credit: MdBabul - stock.adobe.com
Multi-Hit TP53 Mutations Linked With Poor Outcomes in MPN, AML

June 20th 2025

Venetoclax showed “remarkable efficacy” in older patients, with an response rate of 91% in the octogenarian group—similar to what has been reported in younger cohorts. | Image credit: sovova - stock.adobe.com
Venetoclax Effective in Older Patients With CLL

June 20th 2025

Venetoclax duration did not have a significant impact on overall survival based on univariate analysis in patients with AML or MDS. | Image credit: Sviatlana-stock.adobe.com
Venetoclax Duration Does Not Significantly Impact OS in AML or MDS

June 18th 2025

Acute myeloid leukemia cells | Image credit: LASZLO - stock.adobe.com
Revumenib Shows Efficacy in Patients With AML and Genetic Alterations

June 12th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease
January 29th 2020

Dr C. Patrick Carroll on Treating Pain for Patients With Sickle Cell Disease

Managing people with sickle cell disease and complex chronic pain is difficult and requires some trial and error, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia
January 25th 2020

ICER Releases Draft Evidence Report for Sickle Cell, Scoping Document for Hemophilia

Matthew Gavidia
The Institute for Clinical and Economic Review (ICER) published a draft evidence report on crizanlizumab (Adakveo), voxelotor (Oxbryta), and L-glutamine (Endari) for sickle cell disease, as well as a draft scoping document on valoctocogene roxaparvovec, an investigational gene therapy, and emicizumab (Helimbra) for hemophilia.
Site Logo
January 22nd 2020

Managing Vaso-Occlusive Crisis in Sickle Cell Disease: A Look at the Clinical and Economic Burden

https://www.pharmacytimes.org/on-demand/managing-vasoocclusive-crisis-in-sickle-cell-disease-a-look-at-the-clinical-and-economic-burden
Site Logo
January 21st 2020

Biosimilars at ASH 2019: Data on Truxima and Competitors for Eculizumab

Kelly Davio
Results for Truxima, recently launched in the United States, and complement inhibitors were presented at the 61st American Society of Hematology Annual Meeting and Exposition.
Site Logo
January 21st 2020

ASH 2019: Patient-Reported Outcomes, From MOST to FDA Clinical Reviews

Maggie L. Shaw
Symptom burden, functional ability, and quality of life are necessary considerations when treating hematologic malignancies in older patients.
Site Logo
January 21st 2020

ASH 2019: Real-World Evidence and Cost of Care

Maggie L. Shaw Mary Caffrey
Reviews of apixaban in active cancer, Medicare costs after CAR T-cell therapy, and the need for financial assistance for novel therapies.
Site Logo
January 20th 2020

CAR T-Cell Therapy and Beyond: UCART 19 and Anti-BCMA Therapy

Mary Caffrey
A pair of interviews on investigational therapies whose sponsors reported updates at the 61st American Society of Hematology Annual Meeting and Exposition: UCART19 from Servier and a revamped anti-BCMA therapy ide-cel from bluebird bio.
Site Logo
January 20th 2020

CAR T-Cell Therapy and Beyond: Off-the-Shelf Therapies Among Innovations at ASH 2019

Mary Caffrey
Coverage from the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida, featured results for allogeneic or "off the shelf" CAR T-cell treatments and bispecific antibodies.
PBSC Mobilization Yields Sufficient CD34+ Cell Counts in Patients With MM and Lymphoma, Study Finds
January 19th 2020

PBSC Mobilization Yields Sufficient CD34+ Cell Counts in Patients With MM and Lymphoma, Study Finds

Alison Rodriguez
A study identifying the different factors influencing peripheral blood hematopoietic stem cell (PBSC) mobilization and collection in multiple myeloma (MM) and lymphoma cases determined that PBSC mobilization yielded sufficient CD34+ cell counts in both patients with MM and lymphoma, but the failure rates were high.
Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trial
January 17th 2020

Revolutionary Treatment for Sickle Cell Disease Shows Promise in Clinical Trial

Maggie L. Shaw
Sickle cell disease is the most common red blood cell disorder in the United States, having been diagnosed in approximately 100,000 African Americans alone. The lack of oxygen from sickle cell buildup can lead to acute pain crises, joint and organ damage, stroke, and reduced life expectancy.
Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Care
January 16th 2020

Managing Sickle Cell Disease: Innovations, Limitations Within Evolving Standards of Care

Matthew Gavidia
In the evolving treatment landscape for sickle cell disease, current standards of treatment involve 4 drugs that have been FDA approved, with further innovations and limitations adding to the paradigm of care.
Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis
January 15th 2020

Dr Ruben Mesa on Fedratinib's Impact on Health-Related Quality of Life in Myelofibrosis

Research has shown that fedratinib favorably impacts health-related quality of life for patients with myelofibrosis across the board, said Ruben Mesa, MD, director of UT Health San Antonio MD Anderson Cancer Center.
Immunotherapy for Multiple Myeloma: A Report Outlining Currently Approved Monoclonal Antibody Treatments
January 15th 2020

Immunotherapy for Multiple Myeloma: A Report Outlining Currently Approved Monoclonal Antibody Treatments

Alison Rodriguez
Immunotherapy continues to be increasingly used for treating multiple myeloma (MM) with a recent report providing an overview of monoclonal antibodies (mAbs) currently approved for treating MM, as well as, compounds that are under investigation.
Dr C. Patrick Carroll on the Challenges of Treating Sickle Cell Disease–Related Pain With Opioids
January 11th 2020

Dr C. Patrick Carroll on the Challenges of Treating Sickle Cell Disease–Related Pain With Opioids

As a result of the opioid epidemic, there have been instances where it has been difficult to treat patients with pain related to their sickle cell disease because of new policies in place intended to curb addiction and overdoses, said C. Patrick Carroll, MD, director of psychiatric services, Sickle Cell Center for Adults, associate professor of psychiatry, Johns Hopkins Medicine.
Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials
January 3rd 2020

Dr Abby Statler Discusses Restrictive Criteria Excluding Minority Patients From AML Trials

In research presented at the 61st American Society of Hematology Annual Meeting and Exposition, Abby Statler, PhD, MPH, MA, research associate, Cleveland Clinic, and her colleagues found that African Americans with acute myeloid leukemia (AML) may be excluded from clinical trials due to renal dysfunction, despite it having no impact on AML outcomes.
Data Show Fixed-Dose Daunorubicin Plus Cytarabine Leads to Fewer Inpatient Days for Patients With sAML
January 2nd 2020

Data Show Fixed-Dose Daunorubicin Plus Cytarabine Leads to Fewer Inpatient Days for Patients With sAML

Mary Caffrey
An executive with Jazz Pharmaceuticals said the ability to extend survival time in patients with secondary AML, and potentially offer them improved odds for transplant is an advance over traditional chemotherapy.
Dr C. Ola Landgren Discusses Identification of Smoldering Myeloma
December 25th 2019

Dr C. Ola Landgren Discusses Identification of Smoldering Myeloma

The terminology for smoldering myeloma has been around for decades, but more discussion over what it means and who it really applies to is needed, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
Persistence of CAR T Cells Seen in "Next-Generation" Anti-BCMA Therapy, bluebird bio's Ide-cel
December 23rd 2019

Persistence of CAR T Cells Seen in "Next-Generation" Anti-BCMA Therapy, bluebird bio's Ide-cel

Mary Caffrey
The company presented updated phase 1 results for a revamped version of bb2121 that point to sustained responses for patients with relapsed/refractory multiple myeloma.
Leukemia Patients Treated With Anthracyclines Have Increased Risk of Heart Failure in Study
December 23rd 2019

Leukemia Patients Treated With Anthracyclines Have Increased Risk of Heart Failure in Study

Mary Caffrey
As more patients with cancer survive, the risk of cardiac complications due to the effects of therapies has become a concern to oncologists and cardiologists alike.
Unmet Needs and the Future of Myeloma
December 19th 2019

Unmet Needs and the Future of Myeloma

Maintenance Therapy and Relapse/Refractory Treatment
December 19th 2019

Maintenance Therapy and Relapse/Refractory Treatment

MRD Assessment and Prognostic Factors for Myeloma
December 19th 2019

MRD Assessment and Prognostic Factors for Myeloma

Studies With a PI-Based Quadruplet Regimen and Sequencing
December 19th 2019

Studies With a PI-Based Quadruplet Regimen and Sequencing

Treatment of Newly Diagnosed Symptomatic Myeloma and Dosing Regimens
December 19th 2019

Treatment of Newly Diagnosed Symptomatic Myeloma and Dosing Regimens

Proteasome Inhibitor-Based Treatment Regimens
December 19th 2019

Proteasome Inhibitor-Based Treatment Regimens

Transplant Eligibility, NCCN Recommendations, and Sequencing
December 19th 2019

Transplant Eligibility, NCCN Recommendations, and Sequencing

This Week in Managed Care: December 13, 2019
December 13th 2019

This Week in Managed Care: December 13, 2019

This week, the top managed care stories included the White House seeking a truce between CMS Administrator Seema Verma and HHS Secretary Alex Azar; Sanofi will shift its focus from diabetes to cancer drugs; results highlight real-world evidence of chimeric antigen receptor T-cell therapies.
Adding Daratumumab to Carfilzomib, Dexamethasone Improves PFS In Relapsed/Refractory Multiple Myeloma
December 10th 2019

Adding Daratumumab to Carfilzomib, Dexamethasone Improves PFS In Relapsed/Refractory Multiple Myeloma

Mary Caffrey
Although survival rates for multiple myeloma have improved as treatment options have increased, the disease remains incurable, and many patients stop current agents such as lenalidomide or bortezomib due to toxicity. Results of CANDOR involving a triple therapy were presented Tuesday at the 61st American Society of Hematology Annual Meeting and Exposition in Orlando, Florida.
Apixaban Linked to Large Reductions in Major Bleeding, Recurrent VTE in Active Cancer
December 8th 2019

Apixaban Linked to Large Reductions in Major Bleeding, Recurrent VTE in Active Cancer

Maggie L. Shaw
Treating venous thromboembolism (VTE) in patients can be tricky due to greater risks of major bleeding episodes and recurrent VTE.
Fractures in Patients With MM Negatively Impact Survival, Study Says
December 6th 2019

Fractures in Patients With MM Negatively Impact Survival, Study Says

AJMC Staff
The findings show the importance of preventing bone disease in multiple myeloma (MM), the authors said.
<1
...
8910111213141516
...
27>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo